Emcure Pharmaceuticals moves up on getting EIR from USFDA for Sanand facility
Emcure Pharmaceuticals is currently trading at Rs. 1987.10, up by 10.00 points or 0.51% from its previous closing of Rs. 1977.10 on the BSE.
The scrip opened at Rs. 2007.65 and has touched a high and low of Rs. 2047.40 and Rs. 1,980.15 respectively. So far 5703 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 2,047.40 on 10-Aug-2026 and a 52 week low of Rs. 1260.10 on 30-Sep-2025.
Last one week high and low of the scrip stood at Rs. 2,047.40 and Rs. 1911.15 respectively. The current market cap of the company is Rs. 37822.22 crore.
The promoters holding in the company stood at 77.83%, while Institutions and Non-Institutions held 13.34% and 8.83% respectively.
Emcure Pharmaceuticals has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) following an inspection of its formulations manufacturing facility in Sanand, Ahmedabad, Gujarat.
The USFDA conducted this inspection from May 06, 2026 to May 15, 2026. The USFDA has classified the inspection status of the said facility as Voluntary Action Indicated (VAI) and accordingly, the inspection stands closed.
